Skip to main content

Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals

Introduction

Biologics are often used in therapy of DMARDs resistant JIA. The important problem is discontinuation of Biologics therapy due to different reasons.

Objectives

Evaluation of 10 years of the experience of Biologics in children, suffering from juvenile idiopathic arthritis (JIA) in single center focused for reasons of withdrawal.

Methods

The analysis includes data about 435 patients with JIA who have been getting Biologics in 2005 - 2014. The average age of patients is 10,5 years (from 1,5 to 18 years). Disease duration is 7 yrs avg (from 3 to 14 years). Clinical characteristics: soJIA - 70 (17%), JIA with polyarthicular course (poly) - 257 (61%), JIA oligo – 38 (9%), 51 (12%) patients suffered from active uveitis.

Results

During the observation Biologics were withdrawn in 123 cases (98 patients). For some patient we changed Biologics several times: in 21 cases - two times (21% of patients), in 2 cases (2%) - thrice. Distribution of reasons for the Biologics discontinuation is presented in Table 1 below:

Table 1 Table 1

Infliximab was withdrawn more often due to adverse events (infusion reactions), at the beginning of the treatment or several years later. The other reason is secondary inefficiency after 2-5 years of application. Abatacept was cancelled more often for the reason of inefficiency, adverse events were observed rarely. Etanercept was withdrawn in some cases because of uveitis de novo. Adalimumab was withdrawn basically due to organization problem.

Favorable choice of Biologics is changed from 2005 till now. For new initiation we used different biologics in different time. Infliximab was administered in the past (from 2005 to 2012), maximum (14 patients) in 2011. Administration number decrees nowadays (3 in 2013, 1 in 2014). Adalimumab was not commonly administrated before 2011, from 2012 administration count increase from 10-11 per year to 39. Using of Etanercept was increased from 2010 (20-35) and achieved maximum in 2013 (49 patients). Usually we prescribe tocilizumab in systemic JIA and do not change in most cases.

Conclusion

Availability of Biologics therapy was increased during last ten years in Russia. That has improved survival of therapy and has given opportunity of using Biologics with good safety profile.

Disclosure of interest

None declared

Author information

Affiliations

Authors

Corresponding author

Correspondence to Svetlana V Arsenyeva.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Arsenyeva, S.V., Nikishina, I., Kaleda, M. et al. Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals. Pediatr Rheumatol 12, P140 (2014). https://doi.org/10.1186/1546-0096-12-S1-P140

Download citation

Keywords

  • Infliximab
  • Disease Duration
  • Etanercept
  • Safety Profile
  • Juvenile Idiopathic Arthritis